https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ABiosimilar%2F22%2FenTranslations:Biosimilar/22/en - Revision history2026-09-14T13:26:09ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:Biosimilar/22/en&diff=130331&oldid=prevFuzzyBot: Importing a new version from external source2024-03-20T00:54:06Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>The US decided on a different approach, requiring the assignment of a four-letter suffix to the nonproprietary name of the original product to distinguish between innovator drugs and their biosimilars. Japan has similar requirements. The suffix approach has been criticized on the grounds of compromising the INN system and delaying the marketing of biosimilars. Australia decided not to use a 4-letter suffix.</div>FuzzyBot